Company: Amgen Inc

Check out which companies are making headlines after-the-bell Tuesday:    Read More

The Spectrum Pharmaceuticals growth party is over.    Read More

The headwinds that plagued the merger and acquisition market in 2011 are turning into favorable tailwinds for this year.    Read More

Amgen and Celgene, looking to boost oncology offerings, announced separate deals for small biotech companies Thursday, the latest in what analysts expect to be a major wave of biotech mergers.    Read More

As the JPMorgan Health Care conference kicks off this week, one question remains for investors in the biotech space. What’s the next takeover target as large drug makers look to build out their pipeline?   Read More

Stock buybacks can be seen as a sign of confidence or the need to juice the stock. Either way, do they work? Here's a look at recent buybacks — by the numbers.   Read More

Individuals shouldn’t go into debt to buy stock. Neither should companies, even if it’s their own stock. Try telling that to corporate America, which is increasingly turning to debt to fund stock repurchases.    Read More

Nearly half of the companies in the S&P 500 raised dividend payments so far this year, a 38 percent increase from 2010.  At the current level, about 77 percent of the index components, or 393, pay a dividend.   Read More

Corporations are rushing to tap the debt market, drawn by low interest rates and a window of opportunity before year end.    Read More